Retina Foundation of the Southwest
17
5
8
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
5.9%
1 terminated/withdrawn out of 17 trials
88.9%
+2.4% vs industry average
6%
1 trials in Phase 3/4
25%
2 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Oral N-acetylcysteine for Retinitis Pigmentosa
Role: collaborator
Improving Control of Intermittent Exotropia
Role: lead
Binocular Amblyopia Treatment
Role: lead
Video Treatment for Amblyopia
Role: lead
Patch-free Occlusion Therapy
Role: lead
Amblyopia Treatment for Children Aged 8 to 12 Years
Role: lead
Binocular iPad Sub-Study
Role: lead
Improving Control of Alignment in Intermittent Exotropia
Role: lead
Dichoptic Video Treatment for Amblyopia
Role: lead
A Patch Free Treatment for Young Children With Amblyopia
Role: collaborator
Amblyopia and Strabismus Detection Using Retinal Birefringence Imaging
Role: collaborator
Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
Role: lead
Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study
Role: collaborator
Effect of Long-Chain Polyunsaturated Fatty Acid Supplementation on Toddler Cognition
Role: lead
Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner
Role: collaborator
Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa
Role: lead
DHA and X-Linked Retinitis Pigmentosa
Role: lead
All 17 trials loaded